GRTX vs. LCI, TXMD, RNXT, APLM, ITRM, ONCT, VIRX, COCP, INDP, and BCTX
Should you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Lannett (LCI), TherapeuticsMD (TXMD), RenovoRx (RNXT), Apollomics (APLM), Iterum Therapeutics (ITRM), Oncternal Therapeutics (ONCT), Viracta Therapeutics (VIRX), Cocrystal Pharma (COCP), Indaptus Therapeutics (INDP), and BriaCell Therapeutics (BCTX). These companies are all part of the "pharmaceutical preparations" industry.
Galera Therapeutics (NASDAQ:GRTX) and Lannett (NYSE:LCI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings, media sentiment and community ranking.
Galera Therapeutics has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, Lannett has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.
In the previous week, Galera Therapeutics' average media sentiment score of 0.00 equaled Lannett'saverage media sentiment score.
Galera Therapeutics has higher earnings, but lower revenue than Lannett. Galera Therapeutics is trading at a lower price-to-earnings ratio than Lannett, indicating that it is currently the more affordable of the two stocks.
Galera Therapeutics has a net margin of 0.00% compared to Lannett's net margin of -62.40%.
50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 40.3% of Lannett shares are held by institutional investors. 6.9% of Galera Therapeutics shares are held by company insiders. Comparatively, 13.1% of Lannett shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Lannett received 410 more outperform votes than Galera Therapeutics when rated by MarketBeat users. Likewise, 59.59% of users gave Lannett an outperform vote while only 54.35% of users gave Galera Therapeutics an outperform vote.
Summary
Lannett beats Galera Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Galera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galera Therapeutics Competitors List
Related Companies and Tools
